Management of Cancer Therapy Related Vulvovaginal Atrophy

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Genitourinary Syndrome of Menopause
Interventions
DEVICE

Platelet rich plasma

PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.

DEVICE

non cross-linked hyaluronic acid

HA filling is a known modality for rejuvenation

DEVICE

topical HA gel

the standard treatment of vaginal atrophy and dryness

Trial Locations (1)

25211

Alexandria University, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER

NCT05782920 - Management of Cancer Therapy Related Vulvovaginal Atrophy | Biotech Hunter | Biotech Hunter